GlobeNewswire: Signet Healthcare Partners Contains the last 10 of 2 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T20:41:47ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/01/19/2160973/0/en/Signet-Healthcare-and-Bionpharma-Sell-CoreRx-a-Leading-Contract-Development-and-Manufacturer.html?f=22&fvtc=4&fvtv=31100Signet Healthcare and Bionpharma Sell CoreRx, a Leading Contract Development and Manufacturer2021-01-19T19:10:37Z<![CDATA[NEW YORK, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Signet Healthcare Partners and Bionpharma Inc today announced the sale of CoreRx, a global contract development and manufacturing organization ("CDMO"). Following the sale to private equity firm NovaQuest Private Equity, Signet Healthcare Partners will retain a meaningful equity stake in CoreRx. The terms of the transaction are not disclosed.]]>https://www.globenewswire.com/news-release/2017/01/11/905241/0/en/Signet-Healthcare-Partners-Closes-137-2-Million-Life-Science-Fund.html?f=22&fvtc=4&fvtv=31100Signet Healthcare Partners Closes $137.2 Million Life Science Fund2017-01-11T22:52:39Z<![CDATA[NEW YORK, Jan. 11, 2017 (GLOBE NEWSWIRE) -- Signet Healthcare Partners (“Signet”), a private equity fund that provides growth capital to commercial Life Sciences companies, is pleased to announce the closing of Signet Healthcare Partners IV L.P. with $137.2 million of capital commitments.  The firm intends to invest in 10-12 companies and will typically invest $10-15 million per company (with co-investment from its limited partners).  "We are very grateful for the continued support of our loyal investor base during this fundraising, and welcome our new investors," said James Gale, Founding Partner and Managing Director of Signet.]]>